spartan’02 for linux, version 119a (Wavefunction inc)
90
Structured Review
Wavefunction inc
spartan’02 for linux, version 119a
Spartan’02 For Linux, Version 119a, supplied by Wavefunction inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spartan%E2%80%9902+for+linux%2C+version+119a/spartan%E2%80%9902+for+linux++version+119a/pm20030510-65-6-11
Average 90 stars, based on 1 article reviews
Spartan’02 For Linux, Version 119a, supplied by Wavefunction inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/spartan%E2%80%9902+for+linux%2C+version+119a/spartan%E2%80%9902+for+linux++version+119a/pm20030510-65-6-11
Average 90 stars, based on 1 article reviews
spartan’02 for linux, version 119a - by Bioz Stars,
2026-09
90/100 stars
Images
Related Articles
other:Article Title: Cruzain inhibition by hydroxymethylnitrofurazone and nitrofurazone: investigation of a new target in Trypanosoma cruzi. Article Snippet: Chagas’ disease is an important social and medical challenge for people living in Latin America.. Infection caused by the intracellular protozoan Trypanosoma cruzi, the causative agent of Chagas’ disease, persists for the lifetime of the human/mammalian host.. This disease is endemic in 21 countries, mostly in Latin America, with more than 300,000 new cases every year and about million infected people. Article Title: Design, synthesis, and in vivo evaluation of oxamniquine methacrylate and acrylamide prodrugs. Article Snippet: Oxamniquine is an antiparasitic agent commonly used in therapeutics against Schistosoma mansoni.. Although it is well tolerated, some adverse effects justify the search for new compounds with prolonged biological action, so that monomeric and polymeric oxamniquine prodrugs were designed.. Synthetic results assisted by molecular modeling study showed the possibility to obtain the corresponding monomeric forms of the oxamniquine methacrylate (1) and oxamniquine acrylamide (2). |